PFIZER INC.

Pfizer Strategic Plan
Date Submitted: May 25, 2005 Pfizer's Strategic Plan: Overview
Executive Summary
Pfizer is a New York City based major drug producer, ranking first in pharmaceutical sales in the U.S., with 2005 revenues of 56.7 billion. With almost 60 billion in Revenue, Pfizer remains the industry's behemoth, overseeing the most ambitious research agenda for any company in the world. Pfizer's is spending on R&D supports 12,000 scientists. Pfizer's research increased 3 percent in 2004, to 7.7 billion, after a 2003 increase of 44 percent that is attributable to the acquisition of Pharmacia. At the end of 2004, Pfizer had 225 projects in 18 therapeutic areas under active development. Pfizer is studying 145 new
This is a very important global health concern based on the most recent data released in the Scientific Sessions at the AHA National meeting in November 2004 (AHA, 2004).
Environmental Analysis-Internal Environment Proper evaluation of a company's financial statement is very helpful in understanding the company's internal environment. To further assist in understanding the financial statement of a company different types of ratio may be used. Ratios are helpful in the understanding of financial analysis because they seize vital components of the economic performance of the business. Three of the ratios used to determine Pfizer's internal status are profitability, liquidity, and financial leverage. First, profitability evaluation is the assessment of the likelihood that a company will provide investors with a particular rate of return on their investment (Marshall, 2003). The primary focus of financial reporting is on earnings and growth, so it is clear earnings per share (EPS) are the most popular of the financial ratios. The (EPS) measures companies "bottom line" earnings available to the holder of a share of common stock (Marshall, 2003). The last three years Pfizer has seen it's (EPS) fall from (5.75) to (2.2) in 2004. Pfizer has also had to endure some challenging times with their stock price reaching 48-month lows. Pfizer believes